The morbidity of pancreatic ductal adenocarcinoma (PDAC) has been increasing over years, while the treatment efficacy and prognosis of PDAC remain far from satisfying. The newly-ermerged tumor immunotherapy has not only made lots of breakthroughs in various malignancies, but also brought an opportunity to the treatment of pancreatic cancer.PDAC immunotherapies, mainly including vaccine therapy, adoptive T cell thanfer therapy, checkpoint blockade therapy, have achieved a certain effect, however, the clinical outcomes have not been satisfactory. Therefore, the combination of immunotherapies based on different theoretical views is important and is likely to be the trend in the future. Carcinoma associated fibroblast (CAF) is the most common cell in pancreatic cancer stromal component. It will be helpful to develop more potential therapeutic targets by further exploring CAF and the mechanism of fibrosis mediated immunosuppression.
胰腺导管腺癌的发病率逐年上升，但治疗效果和预后却不尽如人意。近年来，逐渐兴起的肿瘤免疫治疗为许多肿瘤带来了治疗突破，也为胰腺癌治疗带来了新的机遇。针对胰腺导管腺癌的主要免疫治疗手段包括胰腺癌疫苗治疗、T细胞过继治疗、检查点抑制治疗等，虽然取得了一定效果，但仍未有令人满意的临床效果。因此，基于不同理论角度的免疫治疗互相配合显得尤为重要，胰腺导管腺癌的联合免疫治疗将是未来免疫疗法的主流。胰腺癌间质中多为肿瘤相关成纤维细胞，进一步了解肿瘤相关成纤维细胞和纤维化介导的胰腺导管腺癌免疫抑制相关机制将有助于开发更多的潜在治疗靶点。.
Keywords: Immune microenvironment; Immunotherapy; Pancreatic neoplasms; Tumor microenvironment.